KR100646594B1 - Composition comprising the extract of C. cassia PRESL having anti-anxiety activity - Google Patents

Abstract

The present invention relates to a broiler extract having anti-anxiety activity and a composition containing the same, the broiler extract of the present invention can be used as a medicine and health functional food having the effect of preventing and treating anxiety caused by various abnormalities of the cranial nervous system. have.

Anti-anxiety, anxiety, broiler, pharmaceutical composition, dietary supplement

Description

Composition comprising the extract of C. cassia PRESL having anti-anxiety activity             

1 is a diagram showing the anti-anxiety effect of broiler crude extract in the cross maze measurement of the mouse, showing the time stayed on the open road (Fig. 1a) and the number of times entered the open road (Fig. Degrees,

2 is a view showing the time stayed on the open road (Fig. 2a), the number of times entered the open road (Fig. 2b) according to the concentration of the broiler crude extract in the case of repeated administration of broiler crude extract in the cross maze measurement of the mouse; ,

Figure 3 is a diagram showing the time stayed on the open road (Fig. 3a), the number of times entered the open road (Fig. 3b) according to the concentration of broiler fraction in the cross maze measurement of the mouse,

4 is a diagram showing the anti-anxiety effect of broiler crude extract when the antagonist of the 5HT1a receptor is administered to the mouse, showing the time stayed on the open road (Fig. 4a), the number of times the open road (Fig. 4b).

The present invention relates to a pharmaceutical composition and a dietary supplement for preventing and treating anxiety caused by abnormalities of various cranial nervous systems as a broiler extract having anti-anxiety activity and a composition containing the same.

As the economic growth rate has recently declined, more and more people are feeling depressed or anxious, and the number of patients with depression or anxiety is increasing in relation to rapidly changing family relationships such as divorce and child problems. Anxiety is a feeling of widespread, very unpleasant and vague anxiety, accompanied by associated physical symptoms (pumping, sweating, etc.) and behavioral symptoms (irritability, pacing, etc.) (Robert F. Scmidt., Human) Physiology , pp 366; Min Sung Gil, Modern Psychiatry , pp238-40; Argyropoulos SV, et al., Pharmacol. Ther. 88 , pp213-27, 2000). Increasingly, patients are receiving specialized psychiatric counseling at hospitals for depression or anxiety, and anti-anxiety sales increased by 200 percent in 2002. It is no exaggeration to say that depression or anxiety can account for most of the mental illnesses of modern people, and many people suffer from it.

When there is anxiety, the entire brain enters an arousal state, thus disrupting peripheral behavior, autonomic nervous system, sensations, and perception. The main organs involved are the cerebral limbic system (especially the hippocampus and the subject society), the cerebral cortex (frontal lobe, temporal lobe), hypothalamus, ascending reticular body and pituitary gland. Recent brain imaging studies have shown that anxiety is associated with disorders in the right hemisphere and other frontal, temporal, and occipital lobe disorders (Robert F. Scmidt., Human Physiology , pp366; Min Sung-gil, Modern Psychiatry , pp238-40). .

Research on therapeutic drugs for anxiety has attracted interest in the development of new drugs, especially serotonin reuptake inhibitors, as well as the reevaluation of old drugs and the expansion of indications. However, clinically effective anti-anxiety drugs have the disadvantage of requiring careful use due to side effects such as sedation and withdrawal, as well as anti-anxiety effects.

The ideal anti-anxiety medication will not cause excessive drowsiness during the daytime, cause physical and mental dependence, and calm the patient.

Representative anti-anxiety agents currently available are benzodiazepine, diazepam, oxazepam, prazepam, lorazepam, alprazolam, helazepam, clonazepam (clonazepam), these drugs are also used primarily for the purpose of sedation and sleep (Yoon Do-jun, side effects of psychiatric drugs, Journal of the Korean Medical Association , 38 (10) , pp1196-1202, 1995). Benzodiazepines are the most commonly used anti-anxiety agents, and their mechanism of action has been shown to increase the affinity of GABA receptors, which are representative inhibitory neurotransmitters in the central nervous system, thus opening adjacent Cl ⁻ channels more often to increase Cl ⁻ ion permeability. . This benzodiazepine is effective immediately, but it is a habit and addictive disadvantage. If the medicine is not used according to the medical treatment, symptoms recur or withdrawal symptoms. Other side effects include drowsiness, ataxia, orthostatic hypotension, respiratory depression, headache, chronic Sleep disorders and liver disease have been reported (Mary J. Mycek, et al., Pharmacology 2nd edition , Lipincott Williams & Wilkins, pp89-93, 2000).

Oriental medicine recognizes depression, anxiety, and nervousness as being caused by fever in the blood and blood, or liver, heart, and rain. It is known that depression, anxiety, insomnia, dreams, fears, cramps, frenzy, falsification. In addition, symptoms such as major (臟 躁), air force (氣 逆), dividers (경계), alert (驚悸) is mainly classified as a panic disorder. Significant mental disorders in response to strong stress, also called giran, are included in the category of depression or anxiety in modern medicine.

These mental nervous system diseases are mainly treated with a drug group called anxin drug (安神 藥物), which reduces depression or anxiety, and has a sedative hypnotic and anticonvulsive effect. About this treatment, herbal medicine says that it can be cured by using mental and physical stabilization in case of surprise, fear, depression or anxiety. Drugs belonging to Ahnsin are known to have the effect of nerve stabilization, although they have their own characteristics (Songbon polar acid, synergistic consideration of neurosis, Oriental Medicine , pp65-8, 1986) ).

Numerous neuropharmacological studies have been reported on drugs with antagonism . In particular, Sanjoin ( Zyziphus jujuba Mill., 酸棗仁 ) is known to have anti-anxiety effects at low doses and to be sedative at high doses (Wu SX, et. al., China Journal of Chinese Materia Medica ., 18 , pp685-704), In addition to the Anxin drug group, Gastrodia elata Blume. (天麻) was induced by reduction of spontaneous momentum and phentobarbital in mouse studies. It is known to have sedative effects such as prolonged sleep (Huang JH, Yi Xue Ke Xue Yuan Xue Bao. , 11 , pp147-50, 1989).

The broiler used in the present invention is the bark or ground skin of Cinnamomum loueirii NEES or C. cassia PRESL. The bark of cinnamon contains 1 to 2% of essential oil (cassa oil), the main component of which is 75 to 90% of cinnamon aldehyde, a small amount of cinnamon alcohol acetic acid ester, Phenylpropanol acetate ester and the like. It also contains mucus, tannins, etc. Broilers are acting on the central nervous system, and haap action, preventive action of juhyeol fluke disease (住血吸蟲病) cinnamon oil also has a strong antibacterial activity (jeongboseop, sinmingyo low, hyangyak Dictionary, Younglim four, pp453-455, 1998).

In the present invention, the broiler extract showed anti-anxiety effect in the mouse, and further confirmed that the anti-anxiety effect of broiler appears through the activity of the 5HT1a receptor, the present invention was completed.

The present invention is to provide a pharmaceutical composition for the prevention and treatment of anxiety caused by the abnormality of various cranial nervous system containing the broiler extract and anti-anxiety effect as an active ingredient.

In accordance with the above object, the present invention provides a pharmaceutical composition for the prevention and treatment of cerebral nervous system-related anxiety, comprising a broiler crude extract having anti-anxiety activity and a pharmaceutically acceptable carrier, diluent or excipient.

The crude extract includes water, a lower alcohol having 1 to 4 carbon atoms, and a polar solvent selected from a mixed solvent thereof, preferably an extract soluble in water.

The present invention also provides a pharmaceutical composition for the prevention and treatment of cerebral nervous system-related anxiety, comprising a soluble extract of a polar solvent having an anti-anxiety activity and comprising a pharmaceutically acceptable carrier, diluent or excipient.

The polar solvent soluble extract is an extract excluding the non-polar solvent soluble part from the crude extract, and a polar solvent selected from water, a lower alcohol having 1 to 4 carbon atoms and a mixed solvent thereof, preferably water or lower alcohol, more preferably Contains extracts soluble in water.

Hereinafter, the present invention will be described in detail.

The broiler extract of the present invention is dried and dried broiler broiler about 1 to 10 times, preferably about 2 to 5 times the volume of water, lower alcohol having 1 to 4 carbon atoms or about 1: 0.1 to 1: 10, preferably a mixed solvent having a mixing ratio of 1: 0.2 to 1: 3 at an extraction temperature of 20 to 100 ° C, preferably 30 to 70 ° C, for about 1 hour to 2 days, preferably 2 hours to 1 day Extraction methods such as hot water extraction, reflux cooling extraction, and ultrasonic extraction, preferably by extraction method of ultrasonic extraction, are repeated once to five times, preferably two to three times, followed by filtration under reduced pressure and filtration. One extract was mixed and concentrated under reduced pressure at 20 to 100 ° C., preferably at 50 to 70 ° C., using a rotary vacuum concentrator to remove the solvent, thereby obtaining crude extract which is a soluble extract according to water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof. To get have.

In addition, the polar solvent soluble extract is 1 to 5 times, preferably 2 to 4 times by adding about 1 to 10 times, preferably about 1 to 5 times the volume of butanol to the water-soluble fraction that has undergone the extraction process of the non-polar solvent soluble component. Butanol soluble fraction and water-soluble fraction may be obtained by fractionation, and the solvent fraction may be concentrated under reduced pressure with a rotary vacuum concentrator to remove the solvent to obtain respective extracts.

In addition, the polar solvent soluble extract, in addition to the extraction separation process, may be directly subjected to Diion Chromatography (Dianion Chromatography) to the crude extract in order to prevent exposure to harmful organic solvents.

In the above method, the filler used as the stationary phase may use SP207, HP20SS or HP 20, but it is preferable to use HP 20 filler,

As the mobile phase solvent, first, water having the highest polarity is transferred, and then a step of substituting with a solvent having a lower polarity is performed, for example, water, water: methanol mixed solvent, methanol, or acetone, which is an additional nonpolar solvent. It is possible to use a developing solvent of, and it is possible to obtain a fraction distilled off, preferably using methanol as a developing solvent.

Fractions spilled through the above method can be obtained fractions having the same or similar component phase as the polar solvent soluble extract by a conventional extraction separation process, fractions obtained through such separation process from organic solvents harmful to humans It has advantages such as exposure prevention effect and simplification of separation process.

Accordingly, the present invention provides a pharmaceutical composition containing the fractions obtained by performing the dianion chromatography method as described above.

In another aspect, the present invention provides the prevention of cerebral nervous system-related anxiety comprising a soluble extract of a polar solvent and a pharmaceutically acceptable carrier, diluent or excipient from the crude extract of broiler having anti-anxiety activity through the extraction separation process as described above; Provided is a therapeutic pharmaceutical composition.

The composition of the present invention comprises a broiler crude extract or a polar solvent soluble extract obtained according to the production method.

The composition of the present invention comprises 0.1 to 50% by weight of the extract relative to the total weight of the composition.

The composition comprising the broiler extract of the present invention may further comprise a suitable carrier, excipient or diluent according to conventional methods.

Carriers, excipients and diluents that may be included in the compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

Compositions comprising extracts according to the invention are each formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories or sterile injectable solutions according to conventional methods. Can be used.

Specifically, when formulated, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, and the like. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ), Lactose, gelatin and the like can be mixed. In addition to simple excipients, lubricants such as magnesium stearate, talc can also be used. Liquid preparations for oral use include suspensions, solvents, emulsions, and syrups, and include various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. Can be. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The extract of the present invention may vary depending on the age, sex, and weight of the patient, but may generally be administered in an amount of 0.01 to 500 mg / kg, preferably 0.1 to 100 mg / kg, divided once or several times daily. . In addition, the dosage of the extract can be increased or decreased depending on the route of administration, the degree of disease, sex, weight, age and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.

The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, humans, etc. by various routes. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

Broiler extract of the present invention is a drug that can be used with confidence even for long-term use for the purpose of prevention because there is little toxicity and side effects.

The present invention provides a dietary supplement for the prevention of cerebral nervous system-related anxiety comprising the broiler extract and food supplements.

The composition containing the broiler extract of the present invention can be used in various ways, such as drugs, foods and beverages for the prevention of cerebral nervous system-related anxiety. Foods to which the extract of the present invention may be added include various foods, for example, beverages, gums, teas, vitamin complexes, dietary supplements, and the like, which are pills, powders, granules, tablets, tablets, capsules or beverages. Available in form.

At this time, the amount of the extract in the food or beverage, in general, may be added to 0.01 to 15% by weight of the total food weight in the case of the health food composition of the present invention, 0.02 to 10g, based on 100ml for the health drink composition, preferably It may be added at a ratio of 0.3 to 1g.

Food supplement additives as defined herein include food additives customary in the art, such as flavorings, flavoring agents, colorants, fillers, stabilizers, and the like, and are exemplified below.

The health beverage composition of the present invention has no particular limitation on the liquid component except for containing the extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; Polysaccharides such as dextrin, cyclodextrin; Conventional sugars such as and the like and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. have. The proportion of such natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

Below, The invention is illustrated in detail by the following examples and experimental examples.

However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Examples and Experimental Examples.

Example 1 Preparation of Broiler Crude Extracts

Broiler, the bark of cinnamon, was purchased from Gyeongdong Market. 300 g of dried broilers are cut and sliced, followed by ultrasonication twice for 3 hours with 3 L of 50% EtOH. After extraction, the resultant was combined and filtered with a filter paper (Whatman, USA), and then concentrated under reduced pressure with a reduced pressure concentrator (EYELA, N-1000, Japan), and then lyophilized to obtain 17.4 g of crude extract of broilers. Obtained.

Example 2 Preparation of Nonpolar Solvent Soluble and Polar Solvent Soluble Using Diion Chromatography

To obtain a fraction of broiler crude extract, 1000 g of broiler crude extract obtained by repeating Example 1 several times using Diionion chromatography (Biotage, Flash 75, USA) was filled with HP20 (Biotage, USA) filler. Starting with water with the highest polarity as the mobile phase, water: methanol (1: 1) mixed solvent and methanol with low polarity were sequentially discharged to concentrate each distillate under reduced pressure, and then lyophilized to obtain 102 g of water soluble effluent. : Methanol (1: 1) mixed solvent soluble effluent 9.6g and methanol soluble effluent were obtained 5.3g.

Reference Example 1. Experimental Animal

Four-week old ICR male mouse (18-20 g) was used by MJ Ltd. It was supplied from (Seoul, Korea) and used for breeding at the animal breeding room of Sungkyunkwan University College of Pharmacy for more than 1 week. The water and feed were consumed freely, and the temperature (23 ± 2 ℃) and humidity (55 ± 10%) were used. And the contrast period (12 hours) were adjusted automatically. 8-16 mice per group were used for each experiment.

Experimental Example 1. Anti-Anxiety Effect of Broiler Crude Extracts by the Cross Maze Method

The cross-maze of the mouse is a 53-cm-high cross-shaped labyrinth that is open at 30 cm in length and 5 cm in width, and has two sides with the same length and width as the two paths facing each other except the central part. Place the gaze of the mouse in the labyrinth that intersects the central part of length 25 cm ² toward the outside of the open path, and then let the mouse voluntarily choose to stay open or blocked. The anxiety symptom was measured for a certain period of time (5 minutes). The broiler crude extract 500, 750, 1000 mg / kg or solvents obtained in Example 1 were orally administered to the mice, respectively, and measured 1 hour later using a camera.

As a result of the experiment, the anti-anxiety effect was confirmed by showing a significant increase of 93 % in the group administered with broiler crude extract 750 mg / kg compared to the group administered with the solvent in the cross maze measurement method (* P <0.05 (See FIG. 1A).

In addition, as a result of performing the same experimental method as described above to confirm the number of times entered into the open path of the mouse, as shown in Figure 1b shows the number of times entered into the open path of 10.2 times in the group administered 750 mg / kg of broiler crude extract The anti-anxiety effect of broiler crude extract was confirmed.

Experimental Example 2. Anti-anxiety effect of repeated administration of broiler crude extract by cross maze method

In order to test the anti-anxiety effect of mice upon repeated administration of broiler crude extract, the same experimental method as in Example 1 was performed. Here, the experiment was performed after oral administration of 50, 100, 200 mg / kg broiler crude extract to the mice once a day for 5 days.

As a result of the experiment, the anti-anxiety effect was confirmed by showing a significant increase of 173 % in the group administered 100 mg of broiler as compared to the group administered with the solvent as shown in Figure 2a.

In addition, as a result of performing the same test method as described above to confirm the number of times entered the open path of the mouse, as shown in Figure 2b compared with the group administered with the solvent as compared to the group administered with broiler 50, 100 mg respectively The anti-anxiety effect of broiler crude extracts was confirmed by showing the number of open paths of 8.5 times.

Experimental Example 3. Anti-Anxiety Effect of Broiler Fractions by Cross Maze Method

The distillation chromatography obtained in Example 2 was used to orally administer the distilled water, water: methanol (1: 1) mixed solvent, and methanol soluble extract at 200 mg / kg in the same manner as in Experimental Example 1. As a result, the anti-anxiety effect of broiler fraction was confirmed by showing the most significant increase of 126 % in the broiler soluble extract administration group compared to the control group (see FIG. 3a).

In addition, as a result of performing the same test method as described above to confirm the number of times entered into the open path of the mouse, the anti-anxiety of the broiler fraction by showing the number of open times of 12.8 times in the group administered the broiler water soluble extract as shown in Figure 3b The effect could be confirmed.

Experimental Example 4. Anti-anxiety effect of broiler extract on administration of 5HT1a receptor antagonist in cross maze assay

By using a mouse maze method, WAY-100635 maleate salt, a selective antagonist for 5HT1a receptor, was administered by subcutaneous injection of 0.3 and 1 mg / kg, respectively, and obtained in Example 1 30 minutes later. One broiler crude extract 750 mg / kg was administered orally. One hour after administration of broiler crude extract, a cross maze experiment was performed. At this time, instead of the WAY-100635 maleate salt, physiological saline was administered as a control.

As a result of the experiment, as shown in Figure 4a, the group administered the broiler crude extract after the administration of 0.3, 1 mg / kg WAY-100635 maleate salt stayed on the open road for 39.6 seconds, 34.1 seconds, respectively, In the case of the control group, they stayed on the open road for 71.4 seconds and exhibited a low anti-anxiety effect in the WAY-100635 maleate salt-administered group. This suggests that the anti-anxiety action of broilers is shown through the activity of 5HT1a receptor.

In addition, as a result of performing the same experimental method as described above to measure the number of enter into the open path of the mouse, WAY-100635 maleate salt 0.3, 1 mg as compared to the control group showed the number of enter into the open path 10 times as shown in Figure 4b / Kg and the broiler crude extract group each 8.7 and 6.9 anti-anxiety showed that the anti-anxiety effect of crude extracts of broilers was inhibited by WAY-100635 maleate, a selective antagonist for 5HT1a receptors.

Experimental Example 5. Acute Toxicity Study

The present invention was divided into three groups of 25 ± 5 g of ICR mice (Korean experimental animals) and 235 ± 10 g of SPF Sprague Dawley (Biogenomics) rats. The broiler extracts of Examples 1 and 2 were intraperitoneally administered at doses of 1000 mg / kg, 100 mg / kg and 10 mg / kg, respectively, and then observed for toxicity for 24 hours.

As a result, no deaths were observed in all four groups, and no significant symptoms were found in weight gain and feed intake. Therefore, it was confirmed that the extract of the present invention is a safe drug.

It describes an example of the formulation of a pharmaceutical composition comprising a broiler extract of the present invention, the present invention is not intended to limit it, but is intended to explain in detail only.

Formulation Example 1 Preparation of Powder

300 mg of dry powder of broiler crude extract of Example 1

Lactose 100 mg

Talc 10 mg

The above ingredients are mixed and filled in an airtight cloth to prepare a powder.

Formulation Example 2 Preparation of Tablet

Dry powder of broiler water soluble extract of Example 2 50 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.

Formulation Example 3 Preparation of Capsule

Dry powder of broiler crude extract of Example 1 50 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.

Formulation Example 4 Preparation of Injection

Dry powder of broiler water soluble extract of Example 2 50 mg

Appropriate sterile distilled water for injection

pH adjuster

According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).

Formulation Example 5 Preparation of Liquid

100 mg of dry powder of broiler crude extract of Example 1

10 g of isomerized sugar

5 g of mannitol

Purified water

According to the conventional method of preparing a liquid solution, each component is added to the purified water to dissolve it, the lemon flavor is added appropriately, the above components are mixed, purified water is added, the whole is adjusted to 100 ml by the addition of purified water, and then filled in a brown bottle. The solution is prepared by sterilization.

Formulation Example 6 Preparation of Healthy Food

1000 mg of dry powder of soluble extract of broiler water of Example 2

Vitamin Mixture

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

Vitamin B ₁ 0.13 mg

Vitamin B ₂ 0.15 mg

Vitamin B ₆ 0.5 mg

0.2 μg of vitamin B ₁₂

Vitamin C 10 mg

10 μg biotin

Nicotinic Acid 1.7 mg

Folate 50 ㎍

Calcium Pantothenate 0.5mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.

Formulation Example 7 Preparation of Healthy Drink

1000 mg of dry powder of broiler crude extract of Example 1

Citric acid 1000 mg

100 g oligosaccharides

Plum concentrate 2 g

1 g of taurine

Add 900 ml of purified water

After mixing the above components according to a conventional healthy beverage manufacturing method, and then stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized and then refrigerated and stored in the present invention For the preparation of healthy beverage compositions.

Although the composition ratio is mixed with a component suitable for a favorite beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

As described above, since the broiler extract of the present invention and the composition containing it as an active ingredient exhibit an anti-anxiety effect, it can be used as a pharmaceutical composition and health functional food for the prevention and treatment of anxiety caused by various cranial nervous system abnormalities. have.

Claims (7)

A pharmaceutical composition for the prevention and treatment of cerebral nervous system-related anxiety comprising crude extracts of broilers that exhibit anti-anxiety activity as an active ingredient, and containing a conventional pharmaceutically acceptable carrier, diluent or excipient. The pharmaceutical composition of claim 1, wherein the crude extract is extracted with water, a lower alcohol having 1 to 4 carbon atoms, and a polar solvent selected from a mixed solvent thereof. The pharmaceutical composition of claim 2, wherein the crude extract is extracted with water. Cranial nervous system containing fractions extracted through Diionion chromatography using water as a developing solvent from broiler crude extract of claim 1 as an active ingredient, and containing a usual pharmaceutically acceptable carrier, diluent or excipient. Pharmaceutical compositions for the prevention and treatment of related anxiety. delete A dietary supplement for the prevention of cerebral nervous system-related anxiety comprising the broiler extract according to claim 1 or 4 and a food acceptable additive. The dietary supplement of claim 6 in the form of a pill, powder, granule, acupuncture, tablet, capsule or beverage.

Images